HGEN News and Press, Humanigen Inc. From 07/26/21

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug ab...

SvetaZi/iStock via Getty Images Telcon RF Pharmaceutical and KPM Tech, the partners of Humanigen ([[HGEN]] -0.7%) for South Korea and the Philippines, have received the regulatory clearance in South Korea to advance a Phase 1 trial for the company’s experimental COVID-19 therapy, ...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced its development and commercialization partners for South Korea and the Philippines, Telcon RF Pharmaceutical, Inc. (“Telcon”) and KPM Tech Co., Ltd. (“KPM Tech”), have received approv...

Humanigen (HGEN) perks up 5% premarket after U.K.'s Medicines and Healthcare Products Regulatory Agency ((MHRA)) accepted its submission for Marketing Authorization of lenzilumab in COVID-19 for expedited rolling review, with assessment expected to occur more rapidly than ...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in June 2021, has been accepted by the United Kingdom’s (UK’s) Medicines and Healthcare Products Regulatory Agency (MHRA...

Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm', today announced that Humanigen has been added to the Russell ...

Humanigen (HGEN) has initiated a rolling review submission for Marketing Authorization ((MA)) by United Kingdom’s Medicines and Healthcare Products Regulatory Agency ((MHRA)) for its lead drug candidate, lenzilumab.This application follows Humanigen’s submission for Emergency Us...

Humanigen begins process for UK authorization through a rolling review submission Application supported by data from the LIVE-AIR phase 3 clinical study Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on prev...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbov...

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced it will present at the 2021 LD Micro Invitational XI, he...